Sign in
Taking peoplePhase 2

Radiation before surgery, with or without cisplatin, for thymoma that cannot be removed

Compares radiation alone with radiation plus chemotherapy before surgery in advanced thymoma.

Key facts

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
Status
Recruiting
Phase
Phase 2
People taking part
178 people, planned
Started
30 Oct 2024
Expected to end
1 May 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • neoadjuvant radiotherapy
  • cisplatin
Record updated
24 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with locally advanced thymoma that a thoracic surgeon says cannot be removed by surgery. Participants get radiotherapy, or radiotherapy with cisplatin, before planned surgery.

Age
18 to 75 years
Sex
All sexes
Disease stage
Thymoma confirmed by tissue test, Masaoka-Koga stage III-IV A, judged not removable by surgery. At least one measurable tumour (RECIST v1.1). ECOG performance status 0-1, meaning fully active or only mildly limited. Heart and lung function good enough for surgery. Expected survival of more than 3 months. Normal organ and bone marrow function.
Earlier treatment
No earlier treatment for thymoma, such as chemotherapy, radiotherapy, surgery or immunotherapy. No earlier radiotherapy to the chest.

Main reasons for not taking part

  • Thymic neuroendocrine tumour
  • Pregnant or breastfeeding women
  • Earlier bone marrow or organ transplant from a donor
  • Other cancer in the past 3 years, or another untreated cancer
  • Investigational drugs or devices within 4 weeks before the first treatment, or being in another interventional study that may affect this one

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Aged ≥18 years and ≤75 years
  • Histologically confirmed thymoma of Masaoka-Koga stage III-IV A
  • Assessed as unresectable thymoma by a thoracic surgeon prior to treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • No prior anti-thymoma treatment, including but not limited to systemic chemotherapy, radiotherapy, surgery, or immunotherapy
  • Presence of at least one measurable lesion according to RECIST v1.1 criteria
  • Cardiopulmonary function compatible with surgery
  • Expected survival of >3 months
  • Comprehensive evaluation completed within 28 days before enrollment in the study, with a full blood cell test obtained within 15 days, demonstrating normal visceral organ function and normal bone marrow function
  • Negative serum or urine pregnancy test for women of childbearing potential within 14 days before study enrollment
  • Willingness of the patient to sign an informed consent form and to adhere to the specified follow-up schedule

Who cannot take part

  • Currently participating in an interventional clinical study that may affect this study, or having received other investigational drugs or devices within 4 weeks prior to the first treatment in this study
  • Previous history of thoracic radiotherapy
  • Deemed unsuitable for three-dimensional conformal or intensity-modulated radiotherapy by a radiation oncology specialist
  • History of allogeneic bone marrow or organ transplantation
  • History of malignancies other than thymoma within the past 3 years, or untreated other primary malignancies
  • Any history or evidence of disease, treatment, or abnormal laboratory values that could interfere with the study results or prevent the participant from completing the study, or other situations deemed unsuitable for enrollment by the investigator
  • Histologically confirmed thymic neuroendocrine tumor
  • Pregnant or breastfeeding women
  • Serious comorbidities that would affect the study treatment

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this prospective, randomized, controlled phase II clinical study is to evaluate the efficacy and safety of neoadjuvant radiotherapy in patients with locally advanced unresectable thymoma. The main questions it aims to answer are:

Read full original descriptionShow less

1. Which treatment method is more effective in improving the radical resection rate: neoadjuvant chemoradiotherapy or neoadjuvant radiotherapy ? 2. The safety and adverse reactions of neoadjuvant radiotherapy? Does the addition of neoadjuvant chemotherapy have an impact on this?

Participants will be randomly divided into two groups: one group will receive neoadjuvant radiotherapy, and the other will receive neoadjuvant chemoradiotherapy. The primary endpoint of the study is to evaluate the radical resection rate (R0) of two groups. The secondary endpoints will include the pathological complete response rate (pCR), 3-year progression-free survival, and safety and toxicities. In addition, this study will explore the feasibility and completion rate of minimally invasive surgical resection.

The 2 groups in the trial

  • the neoadjuvant radiotherapy groupExisting treatment, for comparison

    This group will receive radiotherapy with 40-50 Gy in 20-25 fractions.

    Treatment: neoadjuvant radiotherapy

  • the neoadjuvant chemoradiotherapy groupTreatment being tested

    This group will receive concurrent chemotherapy with radiotherapy. The specific chemotherapy plan is to administer cisplatin intravenously at a dose of 25 mg/m² simultaneously on the first day of radiotherapy, followed by a 6-day rest period. 4-5 cycles of chemotherapy will be conducted, depending on the schedule of the radiotherapy.

    Treatment: neoadjuvant radiotherapy and cisplatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Randomized, Controlled Phase Ⅱ Clinical Trial of Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
Plain-language title
Radiation before surgery, with or without cisplatin, for thymoma that cannot be removedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06924619, who can take part
Record updated
24 April 2025